Tin tức & Cập nhật

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022 bởiTristan Manalac

The use of biosimilars of infliximab (IFX) and adalimumab (ADA) is both safe and effective in children with inflammatory bowel disease (IBD), inducing high rates of failure-free survival with a low incidence of adverse events, according to a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022
Colorectal cancer alters gut microbiome
Colorectal cancer alters gut microbiome
24 Jun 2022 bởiTristan Manalac

Patients with colorectal cancer (CRC) have a substantially altered gut microbiome, characterized by changes in bacterial composition, according to a recent Singapore study. Of note, these alterations persist even after surgery.

Colorectal cancer alters gut microbiome
24 Jun 2022